EW
BBIO icon

Evoke Wealth’s BridgeBio Pharma BBIO Stock Holding History

Evoke Wealth’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-330
Closed -$15K – 1183
2021
Q3 		$15K Hold
330
– – ﹤0.01% 679
2021
Q2 		$20K Hold
330
– – ﹤0.01% 657
2021
Q1 		$20K Buy
+330
New +$21.6K ﹤0.01% 581
2020
Q1 		– Sell
-54
Closed -$1.89K – 1148
2019
Q4 		$1.89K Buy
+54
New +$1.5K ﹤0.01% 1079

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Evoke Wealth's BBIO Position: Q4 2021 in Review

Evoke Wealth sold out of BridgeBio Pharma (BBIO) in Q4 2021, closing a stake of 330 shares — an estimated $15K sold.

Evoke Wealth first reported a position in BBIO in Q4 2019 and held it in 4 quarters. The position peaked at $20K in Q2 2021. 195 funds tracked by Wall St. Rank hold BBIO as of Q4 2021.

  • Evoke Wealth reported no remaining BridgeBio Pharma position as of Q4 2021 after selling out during the quarter.
  • Evoke Wealth sold 330 BridgeBio Pharma shares in Q4 2021, an estimated $15K.
  • Evoke Wealth first reported a position in BridgeBio Pharma in Q4 2019 and held it in 4 quarters.
  • Evoke Wealth's BridgeBio Pharma position peaked at $20K in Q2 2021.
  • 195 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2021.

Based on Evoke Wealth's 13F filing for Q4 2021, filed 9 Feb 2022.